StocksInsight

TFX Stock vs the S&P 500: Returns, Risk and Crash History

Teleflex Incorporated, healthcare (market value $5.9 billion): how it compared with the S&P 500, how it behaved in every crash since 2008, its risk‑adjusted returns and what analysts said. Returns to Oct 30, 2026; analyst data as of Nov 16, 2026.

Published Updated 4 min readHow we research

What changed since Nov 9

Exent re-checks this page every day. Ratings appear 30 days after they are published; the top‑ranked analysts’ calls are not counted here, they are in Gems.

+2 new ratings

Key takeaways

  • TFX returned −59.3% over the 5 years to Oct 30, 2026 versus +75.9% for the S&P 500: it lagged the index.
  • Its 5-year Sharpe ratio was −0.49 against 0.58 for the S&P 500.
  • Its deepest crisis drawdown was −47.4% in the 2022 inflation bear market (S&P 500: −25.4%).
  • Five‑year volatility was 35.1% and beta 0.86.
  • 12 analysts rated it in the past year; 58% of their latest calls were Buy.

What do the best‑ranked analysts on TFX say now? See it in Exent Gems →

Did TFX beat the S&P 500?

Over the 5 years to Oct 30, 2026, Teleflex Incorporated (TFX) returned −59.3% including dividends, versus +75.9% for the S&P 500 (SPY). It lagged the index by 135.2 percentage points, or −16.5% a year against +12.0%.

PeriodTFXS&P 500TFX per yearS&P 500 per yearResult
1 year+13.5%+12.0%+13.5%+12.0%Beat
3 years−22.3%+87.4%−8.1%+23.3%Lagged
5 years−59.3%+75.9%−16.5%+12.0%Lagged
10 years+4.0%+316.3%+0.4%+15.3%Lagged
  • 1 year
    TFX
    +13.5%
    S&P 500
    +12.0%
    TFX per year
    +13.5%
    S&P 500 per year
    +12.0%
    Result
    Beat
  • 3 years
    TFX
    −22.3%
    S&P 500
    +87.4%
    TFX per year
    −8.1%
    S&P 500 per year
    +23.3%
    Result
    Lagged
  • 5 years
    TFX
    −59.3%
    S&P 500
    +75.9%
    TFX per year
    −16.5%
    S&P 500 per year
    +12.0%
    Result
    Lagged
  • 10 years
    TFX
    +4.0%
    S&P 500
    +316.3%
    TFX per year
    +0.4%
    S&P 500 per year
    +15.3%
    Result
    Lagged

Total return with dividends reinvested, from month-end prices to Oct 30, 2026. Beating the index on raw return is only half the story: the next section adjusts for the risk taken. See also how to beat the S&P 500.

What Wall Street analysts say about TFX

In the 12 months to 30 days ago, 12 analysts published 106 ratings on TFX. Their latest calls were 58% Buy, 42% Hold and 0% Sell. 2 of them rank 4★ or higher in Exent’s analyst scoring, which is based on each analyst’s past price‑target hit rate and returns.

The consensus 12‑month price target was $162.33 (range $158.00–$170.00), −2.1% from the last price. Remember that the average analyst’s target is hit only about half the time: how accurate are price targets?

Top‑ranked analyst coveringFirmStarsPrice‑target hit rate
Jayson BedfordRaymond James4.7★46.1%
Anthony PetroneMizuho Securities4.7★45.3%

Ratings are shown with a 30‑day delay. Who the top‑ranked analysts on TFX are, their live calls and the median target of only the top‑rated analysts are in Exent Gems.

The average analyst’s target is reached about 53.0% of the time; Exent Gems is built on the top 50 of Exent’s ranking,where some reached 90% or more over the last two years. Unlock the top 50 analysts.

TFX returns by year vs the S&P 500

TFX beat the S&P 500 in 3 of the 9 full calendar years shown.

YearTFXS&P 500Difference
2026 (to Oct 30, 2026)+15.4%+11.7%+3.7%
2025−30.7%+17.7%−48.4%
2024−28.2%+24.9%−53.1%
2023+0.5%+26.2%−25.7%
2022−23.6%−18.2%−5.4%
2021−19.9%+28.7%−48.6%
2020+9.8%+18.3%−8.5%
2019+46.3%+31.2%+15.1%
2018+4.4%−4.6%+9.0%
2017+55.4%+21.7%+33.7%

TFX risk-adjusted returns: Sharpe, Sortino and volatility

Over 5 years, TFX had a Sharpe ratio of −0.49 against 0.58 for the S&P 500, so it earned less return per unit of risk than the index. Its annualized volatility was 32.6% and its beta 0.86: it tended to move about 0.9× as much as the market.

MetricTFXS&P 500
Annual return−16.5%+12.0%
Volatility (annualized)32.6%15.5%
Sharpe ratio−0.490.58
Sortino ratio−0.610.91
Max drawdown (month-end)−69.9%−23.9%
Beta to the S&P 5000.861.00

Sharpe divides return above cash by total volatility; Sortino counts only downside volatility. Both use monthly returns and the 1–3 month T‑bill ETF (BIL) as the risk‑free rate.

How TFX behaved in past crashes

TFX’s deepest fall in the crises below was −47.4% in the 2022 inflation bear market, against −25.4% for the S&P 500. The last column turns that into money: what a $100,000 position would have lost from peak to trough.

CrisisTFXS&P 500Loss on $100,000
Global financial crisis (2007–09)−44.5%−56.5%−$44,470
2018 trade-war selloff−16.7%−20.2%−$16,720
COVID crash (Feb–Mar 2020)−43.0%−34.1%−$42,980
2022 inflation bear market−47.4%−25.4%−$47,370
2025 tariff selloff−28.4%−19.0%−$28,430
WindowTFX max drawdown
Last 1 year−24.4%
Last 3 years−60.4%
Last 5 years−75.5%
Last 10 years−77.4%

Peak‑to‑trough declines from daily prices inside each crisis window. A crash replay does not predict the next crisis; it shows how much room a holding needs. Run the same replay on a whole portfolio with the crash test.

What moves with TFX, and what doesn’t

Correlation runs from −1 (moves opposite) to +1 (moves in lockstep). Over the last 60 months of monthly returns, TFX’s correlation with the S&P 500 was 0.41, with the Nasdaq‑100 0.23, with long Treasuries (TLT) 0.42 and with gold (GLD) 0.20.

Adding a 5% TFX position to an S&P 500 portfolio would have moved its 5‑year volatility from 15.5% to 15.4%.

Least correlated large capsCorrelationMost correlated large capsCorrelation
APP−0.05UNP0.52
IBKR−0.01BLK0.52
NET0.01HCA0.51
META0.01SYK0.48
VRT0.01DUK0.48

Holdings that are highly correlated behave like one position in a selloff. See how to find hidden overlap.

Latest TFX upgrades, downgrades and price‑target changes

DateRating and targetAnalyst
Nov 6Target raised
Buy
Target $165, was $155
Jayson Bedford
Raymond James
Nov 6Target raised
Hold
Target $160, was $140
Anthony Petrone
Mizuho Securities
Oct 14Target raised
Hold
Target $142, was $135
Richard Newitter
Truist Financial
Oct 14Target cut
Hold
Target $142, was $150
Ravi Misra
Truist Financial
Oct 13Target cut
Hold
Target $140, was $145
Anthony Petrone
Mizuho Securities
Sep 28Upgrade
Hold → Buy
Target $158
Travis Steed
Bank of America Securities

Named analysts’ rating and price‑target changes on TFX in the 5 weeks to Oct 20, 2026, shown 30 days after publication (the free analysts’ calls 3 days after). The top‑ranked analysts’ calls are in Exent Gems. See all of the latest analyst upgrades and downgrades.

The right benchmark for TFX

Exent matches every holding to the index with the most similar risk. For TFX that is MDY. Comparing a holding with an index that carries very different risk makes good results look bad and risky ones look clever. Read why the S&P 500 is the wrong benchmark for most portfolios.

Other healthcare stocks

TickerName5‑year returnVolatility (5y)
LLYEli Lilly and Company+482.3%32.6%
JNJJohnson & Johnson+92.9%16.8%
ABBVAbbVie Inc.+207.1%23.5%
DOCSDoximity, Inc.−52.8%63.3%
RYTMRhythm Pharmaceuticals, Inc.+704.3%74.0%
ERASErasca, Inc.−27.5%84.2%
IMVTImmunovant, Inc.+262.8%67.4%
BDXBecton, Dickinson and Company+18.1%24.4%

Data and methodology

Returns are total returns from month‑end adjusted closing prices (dividends reinvested) through Oct 30, 2026. Crisis drawdowns and trailing maximum drawdowns use daily prices. Analyst coverage counts ratings published in the last 12 months, shown with a 30‑day delay. Full method: Exent methodology.

Company data as of Oct 20, 2026. The move around an earnings report runs from the close before it to the close after it; a price target counts as hit when the stock closed at or beyond it within 12 months (Exent analyst data). Revenue by region and segment, share counts and executive pay come from company filings; insider trades from SEC Form 4, short interest from FINRA, institutional ownership from 13F filings, Congress trades from STOCK Act disclosures filed with the House and Senate, federal contracts from USAspending.gov. Filings from the last 30 days are shown as counts only.

Past performance does not guarantee future results. Historical figures are calculated by Exent from market data and are for education only; they are not investment advice or a recommendation to buy or sell any security.

Check TFX with Exent Gems

Wall Street’s average TFX price target is 2.1% below the latest share price. See what the best‑ranked analysts on TFX say now in Exent Gems.

  1. Exent ranks Wall Street analysts by their past price‑target hit rate and returns, and keeps the best‑ranked few.
  2. Gems shows who the top‑ranked analysts covering TFX are, their live calls and the median target of only the top‑rated analysts.
  3. Gems flags the stocks where several top‑ranked analysts agree: a starting point for your own research, not a promise.

Exent is our product. Educational content, not investment advice.

Frequently asked questions

No. TFX returned +4.0% (+0.4% a year) over the 10 years to Oct 30, 2026, versus +316.3% (+15.3% a year) for the S&P 500, including dividends.

No. As of Oct 20, 2026, TFX (Teleflex Incorporated) is not one of the 503 stocks in the S&P 500.

TFX fell −44.5% from peak to trough during the global financial crisis (2007–09), versus −56.5% for the S&P 500.

TFX fell −43.0% from peak to trough during the covid crash (feb–mar 2020), versus −34.1% for the S&P 500.

TFX fell −47.4% from peak to trough during the 2022 inflation bear market, versus −25.4% for the S&P 500.

Over the 5 years to Oct 30, 2026, TFX’s Sharpe ratio was −0.49 and its Sortino ratio −0.61, versus 0.58 and 0.91 for the S&P 500.

TFX’s 5‑year annualized volatility was 35.1%, higher than the S&P 500’s 17.0%, with a beta of 0.86.

Among large US stocks, the lowest correlations with TFX over the last 60 months were APP (−0.05), IBKR (−0.01), NET (0.01). Its correlation with long Treasuries (TLT) was 0.42 and with gold (GLD) 0.20.

What do the best‑ranked analysts say on TFX now?

Exent ranks Wall Street analysts by their track record. Gems shows who the top‑ranked analysts on TFX are, their latest calls and the stocks where several of them agree.

See this week’s GemsLimited offer$1.95 for full access· full access

Educational content, not investment advice. Examples are illustrative; past performance does not guarantee future results.

DISCLAIMER: Exent AI is an informational research platform and does not provide investment advice, financial advice, or act as an investment adviser, broker-dealer, or fiduciary. All content, analytics, and model outputs are provided for educational and informational purposes only and should not be relied upon as a recommendation to buy, sell, or hold any financial instrument. Investing involves risk, including the possible loss of principal. Exent AI does not execute trades, hold customer funds, or provide brokerage services. Past performance and hypothetical results are not indicative of future results. Third-party data and AI-generated outputs may be incomplete or inaccurate.